Zydus Lifesciences secures USFDA approval for Estradiol Transdermal System to treat menopause symptoms

Published On 2022-12-02 10:13 GMT   |   Update On 2022-12-02 10:13 GMT
Advertisement

Ahmedabad: Pharma major Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (USRLD: Vivelle-Dot Transdermal System).

Estradiol Transdermal System is indicated to treat moderate to severe symptoms of menopause which includes feelings of warmth in the face, neck, and chest or sudden strong feelings of heat, hot flushes, and vaginal dryness in women.

Advertisement

The drug will be manufactured at the group's formulation manufacturing facility at Moraiya, Ahmedabad, India.

The group now has 336 approvals and has so far filed over 431* ANDAs since the commencement of the filing process in FY 2003-04.

Read also: USFDA nod to Zydus Lifesciences Migraine drug Topiramate Extended Release

Zydus Lifesciences Limited, formerly Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad. The company is primarily engaged in the manufacture of generic drugs. Zydus group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim in India and in the US and Brazil.

Zydus' global business has a strong presence in the regulated markets of the US, Europe (France and Spain), and the high-profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.

Read also: Zydus Lifesciences appoints Akhil Monappa, Upasana Kamineni Konidela as new Independent Directors

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News